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Microbial tryptophan catabolites in health
and disease
Henrik M. Roager1,2 & Tine R. Licht 2
Accumulating evidence implicates metabolites produced by gut microbes as crucial media-
tors of diet-induced host-microbial cross-talk. Here, we review emerging data suggesting that
microbial tryptophan catabolites resulting from proteolysis are inﬂuencing host health. These
metabolites are suggested to activate the immune system through binding to the aryl
hydrocarbon receptor (AHR), enhance the intestinal epithelial barrier, stimulate gastro-
intestinal motility, as well as secretion of gut hormones, exert anti-inﬂammatory, anti-
oxidative or toxic effects in systemic circulation, and putatively modulate gut microbial
composition. Tryptophan catabolites thus affect various physiological processes and may
contribute to intestinal and systemic homeostasis in health and disease.
The diverse and dynamic microbial community of the human gastrointestinal tract plays avital role in health and nutrition of the host1. A mutualistic relationship between host andgut microbiota relies on complex molecular cross-talk, which is fundamental for intestinal
homeostasis. Although recent advances in characterizing the composition and function of the
gut microbiota have yielded numerous new ﬁndings about the role of the gut microbiota in
human health, only few microbiota-generated metabolites affecting host physiology have been
identiﬁed, but these include short-chain fatty acids (SCFA) originating from bacterial degra-
dation of dietary ﬁber2, secondary bile acids originating from bacterial conversion of bile acids in
the colon3, and trimethylamine-N-oxide (TMAO), which is a product of microbial-host co-
metabolism of nutrients such as phosphatidylcholine, choline, and L-carnitine, present in high-
fat foods4,5. The role of bacterial metabolites originating from proteolysis on host physiology has
however received only scarce attention. Although bacterial protein degradation products in
general have been considered to be deleterious for the host6, recent data suggests that tryptophan
catabolites generated by the gut microbiota are important contributors to intestinal homeostasis.
Here, we review recent discoveries related to microbial tryptophan catabolites and discuss future
efforts to explore their potential role in mediating microbe-host interactions (Fig. 1). Since
available studies linking tryptophan catabolites with health are typically associative or originate
from mouse models, more research is needed to provide tangible connections between trypto-
phan catabolites and human health.
Bacterial tryptophan catabolism in the gut
Tryptophan is an essential amino acid for humans, and is supplied by dietary protein (Box 1).
Although the majority of ingested protein is digested and absorbed in the small intestine7,
dependent on intake, signiﬁcant amounts of proteins and amino acids (6–18 g/day) may reach
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the colon8, where a range of commensal bacteria degrade them.
Bacterial protein catabolism increases with increased protein
intake, carbohydrate depletion in the colon, increased colonic pH
and prolonged colonic transit time9–12. The gradual depletion of
carbohydrate substrates occurring from the proximal to the distal
colon causes a shift in bacterial catabolism from saccharolytic to
proteolytic fermentation10. In agreement herewith, concentra-
tions of phenolic compounds from degradation of aromatic
amino acids in the human gut content are more than fourfold
higher in the distal colon than in the proximal colon12. Bacterial
proteolytic specialists are reported to have lower growth potential
than generalists and saccharolytic/lipolytic specialists, suggesting
that proteolytic specialists thrive when the ecological pressure for
fast growth is decreased13. However, the degradation of trypto-
phan appears not to be limited to proteolytic specialists or to the
distal colon as for example the Lactobacilli catabolize tryptophan
in the stomach and ileum of mice14. Several bacterial species have
been reported to be able to convert tryptophan into indole and
indole derivatives (Table 1). Already in 1897, tryptophan was
found to be converted into indole by Bacillus coli (now Escher-
ichia coli) and Asiatic cholera (now Vibrio cholerae)15. Later, the
production of indole has been used as a diagnostic marker to
distinguish E. coli from other enteric bacteria. Because indole has
been known for more than 100 years, numerous indole-
producing species have been identiﬁed as described in a pre-
vious review16; therefore these are not discussed in details here.
Brieﬂy, indole formation occurs via the action of the enzyme
tryptophanase (TnaA), which is expressed in many Gram-nega-
tive, as well as Gram-positive bacterial species including Escher-
ichia coli, Clostridium spp. and Bacteroides spp.12,16–18. More
recently, a number of studies have shown that gut microbial
species produce a variety of tryptophan catabolites via various
other metabolic pathways (Fig. 2). For example, Clostridium
sporogenes converts tryptophan into tryptamine, indolelactic acid
(ILA) and indolepropionic acid (IPA)19–21. Likewise, Peptos-
treptococcus spp. including P. russellii, P. anaerobius and P. sto-
matis are known to convert tryptophan to indoleacrylic acid (IA)
and IPA, possibly due to the presence of the phenyllactate
dehydratase gene cluster (ﬂdAIBC) on the chromosome of these
species22. Indeed, a homologue of this cluster is found to be
responsible for the conversion of tryptophan into ILA and IPA in
C. sporogenes21. Furthermore, homologue gene-clusters were
found in Clostridium cadaveris, Clostridium botulinum and Pep-
tostreptococcus anaerobius21 in agreement with their capability to
produce IPA17,21,22. Another group of bacteria capable of con-
verting tryptophan is Lactobacilli. Lactobacillus spp. convert
tryptophan to indolealdehyde (IAld) and ILA via the aromatic
amino acid aminotransferase (ArAT) and an indolelactic acid
dehydrogenase (ILDH)14,23,24. Ruminococcus gnavus converts
tryptophan into tryptamine by the action of a tryptophan dec-
arboxylase enzyme20. Several Bacteroides species, as well as
Clostridium bartlettii have been reported to produce ILA and
indoleacetic acid (IAA)25, whereas Biﬁdobacterium spp. have
been reported to produce ILA25,26. Finally, the common intestinal
metabolite 3-methylindole (skatole), which have been extensively
studied as the cause of off-ﬂavor in pork, is generated by dec-
arboxylation of IAA by Bacteroides spp. and Clostridium
spp.12,17,25,27. Although several species are able to metabolize
tryptophan in vitro (Table 1), studies linking the abundances of
bacterial species with concentrations of tryptophan catabolites in
humans are still needed to identify the main tryptophan cata-
bolite producers in the human gut. Indole and IAA are detected
in human fecal samples of healthy adults at mean concentrations
of 2.6 mM28 and 5 µM29, respectively. However, the concentra-
tions of other tryptophan catabolites (IPA, ILA, IAld, tryptamine
and IA) in the human gut have to our knowledge not been
assessed. In serum, mean concentrations in healthy adults have
previously reported for IAA (1.3 µM), IPA (1.0 µM), and ILA
(0.15 µM)30, while a recent study reported a mean serum IPA
concentration of 50 nM31. Additionally, the mean concentrations
of microbial tryptophan catabolites in the urine of pregnant
women were recently reported for IAA (61 µM), methyl-IAA (8
µM), tryptamine (9 µM), and methyl-IPA (0.5 µM)32. Despite
differences in the reported concentrations, these studies suggest
that in adults, indole is the most abundant microbial tryptophan
catabolite, followed by IAA and IPA. The availability of methods
for determination of concentrations of microbial tryptophan
catabolites in biological specimens is however currently
limited28,32 and better quantitative analytical methods targeting a
larger variety of microbial tryptophan metabolites are needed.
Such methods will enable the comparison of metabolite con-
centrations across biological compartments (i.e. feces, blood and
urine) and between different human populations.
Mechanisms of action of microbial tryptophan catabolites
A growing body of literature suggests that tryptophan catabolites
generated by the gut microbiota are important signaling mole-
cules in microbial communities, as well as in host-microbial
cross-talk, and may contribute to intestinal and systemic home-
ostasis (Fig. 1).
Microbial beneﬁts of tryptophan metabolism
While the interaction of intestinal bacterial tryptophan metabo-
lites with the host has received an increasing amount of attention
in recent years as reviewed in the following sections, knowledge
about the beneﬁt of tryptophan metabolism to the intestinal
microbes themselves is limited. Tryptophan has a multitude of
metabolic functions, for example, it is incorporated into poly-
peptide chains of bacterial enzymes and serves as a precursor of
the cofactor NAD33. However, most important in the rich
intestinal environment is probably the bacterial need for main-
tenance of redox homeostasis. In the gut, the bacteria generate
ATP from fermentation of carbohydrates, which typically
Box 1 Some facts about tryptophan
● Tryptophan is one of the nine so-called essential amino acids, which the human organism cannot synthesize, and which therefore must be supplied in
the diet.
● Tryptophan is the only amino acid that contains the structure of an indole, i.e. a bicyclic compound, consisting of a six-membered benzene ring fused
to a ﬁve-membered, N- containing, pyrrole ring.
● Tryptophan is a part of dietary proteins, and is thus high in protein-rich foods such as meat, ﬁsh, eggs, cheese, beans, and nuts.
● Tryptophan is taken up in the small intestine, but the fraction that reaches the colon can be catabolized by the gut bacteria resulting in a variety of
indole-derivatives (Fig. 1).
● While bacterial products of protein degradation are generally associated with detrimental effects, new research suggests that microbial tryptophan
catabolites may also have a positive impact on host physiology.
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involves oxidative steps. Compensating reductions must thus be
carried out. As recently reviewed for food fermentation involving
lactic acid bacteria34, microbes apply a multitude of different
reactions in order to ﬁnd ultimate electron acceptors allowing
them to balance their fermentative metabolism in the absence of
oxygen. Similarly in the gut, indole pyruvate generated by
transamination of tryptophan may thus be applied as electron
acceptor and reduced to ILA by action of the ILA dehydrogenase
(Fig. 2). Such ﬁne-tuning reactions might thus equilibrate the
redox potential and give microbes a competitive advantage in the
gut. Additionally, bacterial cross-feeding on degradation products
of aromatic amino acids is likely to occur in the human colon35,
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Fig. 1 Mechanisms of action of microbial tryptophan catabolites on host physiology. Degradation of dietary proteins leads to the release of tryptophan,
which is converted into various catabolites by the gut microbiota. The tryptophan catabolites include indole, tryptamine, indoleethanol (IE), indolepropionic
acid (IPA), indolelactic acid (ILA), indoleacetic acid (IAA), skatole, indolealdehyde (IAld) and indoleacrylic acid (IA) and may affect host physiology in
numerous ways. Indole, IPA and IA affect mucosal homeostasis by decreased intestinal permeability possibly mediated by the pregnane X receptor (PXR).
Indole induces the release of glucagon-like peptide 1 (GLP-1) in enteroendocrine L-cells. GLP-1 is known to suppress appetite, insulin secretion and to slow
gastric emptying. Several tryptophan catabolites act on the aryl hydrocarbon receptor (AHR) found in intestinal immune cells and thereby alter innate and
adaptive immune responses in a ligand-speciﬁc fashion (e.g. IAld induces increased production of interleukin-22 (IL-22) via AHR activation). Tryptamine
induces the release of 5-hydroxytryptamine (5-HT, serotonin) by enterochromafﬁn cells. 5-HT stimulates gastrointestinal motility by acting on enteric
nervous system neurons. Tryptophan catabolites are absorbed through the intestinal epithelium and enter the bloodstream where some (e.g. IPA, IE, IA)
have anti-oxidative and anti-inﬂammatory effects, whereas indoxyl-sulfate (IS), which is produced in the liver from indole by the actions of CYP2E1 and
sulfotransferases (SULT), has cytotoxic effects in high concentrations
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and may provide speciﬁc bacteria with a growth advantage in the
highly competitive gut ecosystem.
Tryptophan catabolites as signals and antimicrobial agents
Indole is well-described as an intercellular signal molecule that
appears to be important in microbial communities by affecting
spore formation, plasmid stability, drug resistance, bioﬁlm for-
mation, and virulence16. Similarly, indoleethanol (IE, tryptophol)
has been identiﬁed as a quorum sensing molecule in fungi36.
This metabolite also exerts antimicrobial activity towards Sta-
phylococcus aureus, Salmonella enterica and Lactobacillus
plantarum37,38. Moreover, IE inhibits bacteriophage replication in
a thermophilic bacterium, Geobacillus sp. E26339, virus replica-
tion in shrimps40, and proliferation of parasitic protozoa41. Also
ILA is reported to have antifungal activity against Penicillium
strains42 and anti-bacterial activity against E. coli and B. cereus43.
Furthermore, there is evidence suggesting that indoles affect the
survival of the nematode Caenorhabditis elegans44,45. Collectively,
these diverse examples suggest that indoles play a role as mod-
ulators of microbial gut communities across kingdoms including
bacteria, fungi and viruses. Yet, whether the tryptophan catabo-
lites modulate also the microbial community of the mammalian
gut remains unexplored.
Table 1 Gut bacterial species reported to produce tryptophan catabolites
Metabolite Producers References
Indole Bacteroides thetaiotaomicron
Bacteroides ovatus
Clostridium limosum
Clostridium bifermentans
Clostridium malenomenatum
Clostridium lentoputrescens
Clostridium tetani
Clostridium tetanomorphum
Clostridium ghoni
Clostridium sordellii
Desulfovibrio vulgaris
Enterococcus faecalis
Escherichia coli
Fusobacterium nucleatum
Haemophilus inﬂuenza
Peptostreptococcus asscharolyticus
… for more see16
12,16–18
3-methylindole (Skatole) Bacteroides thetaiotaomicron
Butyrivibrio ﬁbrisolvens
Clostridium bartlettii
Clostridium scatologenes
Clostridium drakei
Eubacterium cylindroides
Eubacterium rectale
Lactobacillus spp.
Megamonas hypermegale
Parabacteroides distasonis
25,27,118
Indoleacetic acid (IAA) Bacteroides thetaiotaomicron
Bacteroides eggerthii
Bacteroides ovatus
Bacteroides fragilis
Biﬁdobacterium adolescentis
Biﬁdobacterium longum subsp. longum
Biﬁdobacterium pseudolongum
Clostridium bartlettii
Clostridium difﬁcile
Clostridium lituseburense
Clostridium paraputriﬁcum
Clostridium perfringens
Clostridium putrefaciens
Clostridium saccharolyticum
Clostridium sticklandii
Clostridium subterminale
Escherichia coli
Eubacterium hallii
Eubacterium cylindroides
Parabacteroides distasonis
Peptostreptococcus asscharolyticus
12,17,25
Indoleacrylic acid (IA) Clostridium sporogenes
Peptostreptococcus russellii
Peptostreptococcus anaerobius
Peptostreptococcus stomatis
21,22
Indolealdehyde (IAld) Lactobacillus acidophilus
Lactobacillus murinus
Lactobacillus reuteri
14,23,24
Indoleethanol (IE) - -
Indolelactic acid (ILA) Anaerostipes hadrus
Anaerostipes caccae
Bacteroides thetaiotaomicron
Bacteroides eggerthii
Bacteroides ovatus
Bacteroides fragilis
Biﬁdobacterium adolescentis
Biﬁdobacterium biﬁdum
Biﬁdobacterium longum subsp. infantis
Biﬁdobacterium longum subsp. longum
Biﬁdobacterium pseudolongum
Clostridium bartlettii
Clostridium perfringens
Clostridium sporogenes
Clostridium saccharolyticum
Escherichia coli
Eubacterium rectale
Eubacterium cylindroides
Faecalibacterium prausnitzii
Lactobacillus murinus
Lactobacillus paracasei
Lactobacillus reuteri
Megamonas hypermegale
Parabacteroides distasonis
Peptostreptococcus asscharolyticus
12,21,23–26,42
Indolepropionic acid (IPA) Clostridium botulinum
Clostridium caloritolerans
Clostridium paraputriﬁcum
Clostridium sporogenes
Clostridium cadvareris
Peptostreptococcus asscharolyticus
Peptostreptococcus russellii
Peptostreptococcus anaerobius
Peptostreptococcus stomatis
17,19–22
Tryptamine Clostridium sporogenes
Ruminococcus gnavus
20
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Tryptophan catabolites as aryl hydrocarbon receptor ligands
In recent years it has become evident that bacterial tryptophan
catabolites including tryptamine, skatole, IAA, IA, IAld, and
ILA are acting as ligands of the aryl hydrocarbon receptor
(AHR)14,23,46,47. AHR is a transcription factor widely expressed
by cells in the immune system48 and a number of studies have
demonstrated that AHR activation alters innate and adaptive
immune responses in a ligand-speciﬁc fashion49–51. Importantly,
the afﬁnities of tryptophan catabolites for the AHR differ between
mice and humans47 and even within laboratory mouse strains,
where four alleles encoding different forms of the AHR are
known to exist52. Whereas the rodent AHR has been found to
bind the exogenous ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD or dioxin) with approximately 10-fold higher afﬁnity
than the human AHR53, recent studies suggest that the human
AHR has higher afﬁnity than the mouse AHR for a number of
tryptophan-derived ligands47. Together, these studies reveal that
rodent AHR and human AHR exhibit different ligand selectivity,
which is very important to consider given that predictions about
AHR ligand-receptor interactions in humans are often based on
rodent studies. Furthermore, in intestinal cell line models, the
tryptophan catabolites have been found to be either agonists or
antagonists depending on their molecular structure46,54. Recent
studies have underlined that indole-induced AHR activation may
be one way that bacteria contribute to mucosal homeostasis.
Lactobacillus spp. were found to regulate interleukin (IL)-22
mucosal homeostasis via IAld-mediated activation of AHR, and
thereby to protect mice against mucosal candidiasis14. In addi-
tion, treatment of mice with three Lactobacillus strains capable of
metabolizing tryptophan attenuated intestinal inﬂammation via
AHR activation, as the effects were abrogated in the presence of
an AHR antagonist29. Also Lactobacillus bulgaricus OLL1181 was
found to activate the AHR pathway and inhibit colitis in a mouse
model55. Further deciphering the mechanisms, a recent study in
mice revealed that Lactobacillus reuteri via IAld and ILA activates
AHR, which reprogram intraepithelial CD4+ T helper cells into
immunoregulatory T cells (CD4+ CD8αα double-positive
intraepithelial lymphocytes)23. Additionally, ILA was found to
inhibit mouse polarization of T helper 17 (TH17) cells in vitro24.
Together these studies suggest that tryptophan catabolites via
AHR affect the differentiation of naive CD4+ T helper cells into
regulatory T (Treg) cells and TH17 cells. The TH17/Treg balance
plays an important role in autoimmune and inﬂammatory dis-
eases56. Thus, the discovery of tryptophan catabolites as AHR
ligands may provide new insight about how microbial metabolites
affect the immune system in the gut, as well as in systemic cir-
culation. In addition, indoles provided by commensal bacteria
have been found to improve the health of a range of different
organisms including Caenorhabditis elegans, Drosophila melano-
gaster and mice in an AHR-dependent way57. This raises the
intriguing possibility that tryptophan catabolites via AHR may
reduce frailty and improve health also in humans.
Tryptophan catabolites and intestinal barrier functions
Both in vitro and in vivo studies have indicated that indole
enhances intestinal epithelial barrier functions by increasing
expression of genes involved in maintenance of epithelial cell
structure and function58,59. Moreover, also IPA was found to
regulate intestinal barrier function in vivo in mice by acting as a
ligand for the xenobiotic sensor, pregnane X receptor (PXR),
particularly in the presence of indole60. Activation of PXR has
been shown to protect the barrier function in a mouse model of
colitis61. In addition, IPA was found to reduce intestinal per-
meability in mice fed a high fat diet62. Further emphasizing the
link between IPA and intestinal barrier function, a recent study
colonized germ-free mice with either a wild-type or ﬂdC mutant
C. sporogenes (IPA production in C. sporogenes require an intact
ﬂdC gene), and showed that the ﬂdC-colonized mice exhibited
signiﬁcantly increased permeability to FITC-dextran compared to
their wild-type-colonized counterparts, concordant with depleted
levels of luminal IPA21. Also IA has recently been shown to
promote intestinal epithelial barrier function and mitigate
inﬂammatory responses in mice by promoting goblet cell differ-
entiation and mucus production, possibly mediated by AHR
activation22. Collectively, these studies suggest that tryptophan
catabolites signal through PXR and AHR to fortify the intestinal
epithelial barrier function.
Tryptophan catabolites and gut hormone secretion
Indole has been seen to function as a signaling molecule, which is
able to modulate the secretion of glucagon-like peptide-1 (GLP-1)
from immortalized and primary mouse colonic enteroendocrine
L cells63. GLP-1 plays a critical role in stimulating insulin
secretion from pancreatic beta cells, suppressing appetite and
slowing gastric emptying64. Thus, intestinal levels of indole may
this way affect appetite. Higher serum concentrations of IPA have
recently been associated with reduced prevalence of type 2
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Fig. 2Microbial generation of tryptophan catabolites in the human gut. Overview of the different ways microbes degrade tryptophan in the human gut. The
metabolites that are most often found in the human gut are colored in green. Dashed lines represent pathways where no enzymes have been identiﬁed
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diabetes and better insulin secretion and sensitivity65, which adds
to the evidence pointing towards a putative role of indoles in
modulating glucose metabolism, possibly via L cell-induced
secretion of GLP-1. In line with this, a recent study found that
rats fed a diet containing IPA had signiﬁcantly lower fasting
blood glucose level compared to rats fed a control diet66.
Although the sensing of indole derivatives by L-cells remains
elusive, it seems plausible that G protein-coupled receptors
(GPCRs), which are responsive to a range of nutrients and other
food components67, may also be responsive to microbial meta-
bolites including tryptophan catabolites as reviewed elsewhere68.
Nonetheless, these studies call for more research to be done to
elucidate how tryptophan catabolites may modulate the enter-
oendocrine system and metabolic homeostasis including glucose
metabolism.
Tryptamine and gastrointestinal motility
Tryptamine, a tryptophan catabolite produced by C. sporogenes
and Ruminococcus gnavus20, is a β-arylamine neurotransmitter,
which may inﬂuence gut health. In the gut, tryptamine is
known to induce the release of the neurotransmitter 5-
hydroxytryptamine (5-HT, serotonin) by enterochromafﬁn
cells69, which are located at the mucosal surfaces70. 5-HT sti-
mulates gastrointestinal motility by acting on enteric nervous
system neurons70. In addition, using an Ussing chamber with a
segment of proximal-mid murine colon mucosa, it was found that
tryptamine itself induced a signiﬁcant change in short circuit
current, conﬁrming that it can affect ion secretion in intestinal
epithelial cells20, which plays an important role in gastrointestinal
motility. Thus, tryptamine may act as a signaling molecule that
affects intestinal transit time, which is strongly associated with the
gut microbial composition, diversity and metabolism in
humans10,71. Whether bacterial production of tryptamine plays a
role in the pathogenesis of irritable bowel syndrome, which often
manifests as either chronic diarrhea or chronic constipation72,
currently remains unanswered. One species of particular interest
could be R. gnavus, which is over-represented in inﬂammatory
bowel disease (IBD)73,74, produces tryptamine20 and utilizes
mucin75, suggesting that it thrives in close proximity with the
enterochromafﬁn cells. Indeed, R. gnavus mono-associated mice
showed induction of several genes involved in tryptophan
metabolism as compared to germ-free mice76. As R. gnavus is a
common species of the gut microbiota found in around 90% of
adults77 and infants78, the ability of this species to produce
tryptamine may inﬂuence human health.
Tryptophan catabolites in the systemic circulation
Tryptophan catabolites may also systemically affect host phy-
siology as they are absorbed through the intestinal epithelium and
enter the bloodstream19 before they are excreted in the urine10,32.
Association analyses between the human gut microbiome and
ex vivo cytokine responses in whole blood upon microbial sti-
mulations pinpointed a negative association between interferon
gamma (IFNγ) production and bacterial genes responsible for the
conversion of tryptophan into IE79, suggesting that IE has anti-
inﬂammatory properties. Previous studies have suggested IPA as
a scavenger of hydroxyl radicals80, and a protector against oxi-
dative damage in different tissues81–83. However a recent study
found that IA, but not IPA, had anti-inﬂammatory and anti-
oxidative effects in LPS-activated human peripheral blood
mononuclear cells (PBMCs) expressed as reduced IL-6 and IL-1β
secretion and activation of the NRF2-ARE pathway22, a pathway
suggested to be a therapeutic target towards prevention of neu-
rodegenerative disorders84 and IBD85. Similarly, IAA and tryp-
tamine attenuated pro-inﬂammatory cytokine responses in
murine macrophage cultures and hepatocyte cultures in an AHR-
dependent way86, suggesting that microbial tryptophan catabo-
lites could inﬂuence inﬂammatory responses in the liver as well.
The effects of tryptophan catabolites on production of cytokines
may depend on AHR activation, since it has been shown that
AHR signaling modiﬁes Toll-like receptor (TLR)-regulated
responses in human dendritic cells87. Adding to the complexity, it
has been reported that AHR-mediated gene induction may be
enhanced by SCFA88.
Although indoles in general appear to be beneﬁcial, an
exception to this is indoxyl sulfate (IS), which is a host-microbial
co-metabolite generated from indole in the liver by the actions of
cytochrome P450 enzymes, including CYP2E1, and sulfo-
transferase (SULT)89. This metabolite is typically characterized as
a uremic toxin that accumulates in patients with chronic kidney
disease (CKD) with serum concentrations around 100 µM com-
pared to 2 µM in healthy adults90,91. IS is a potent agonist for
AHR92, which induces tubulointerstitial ﬁbrosis93, glomerular
sclerosis94, vascular endothelial cell dysfunction95 and oxidative
stress in endothelial cells96. IS is undetectable in germ-free mice,
as the production of IS depends on commensal bacteria19. Thus,
manipulation of the gut microbial tryptophan catabolism may be
one strategy to lower circulating levels of IS, as recently demon-
strated in gnotobiotic and conventional mice18. Whether diver-
sion of intestinal tryptophan catabolism away from IS will be
beneﬁcial in renal diseases needs to be determined in future
studies.
Tryptophan catabolites in health and diseases
In light of the effects of tryptophan catabolites on various phy-
siological processes, we discuss three areas in which tryptophan
catabolites may play a vital role.
Early life
In light of the great changes of the composition of the gut
microbiota occurring during the ﬁrst years of life97,98, which to a
large extent is driven by changes in diet99,100, it is highly likely
that the gut microbial tryptophan metabolism also changes in this
period. Indeed, indole-producing E. coli are known to be abun-
dant in the ﬁrst week of life101, whereafter Biﬁdobacterium spe-
cies, which are reported to be able to produce ILA26, start
dominating the gut microbiome of breastfed infants100–102. Later,
as complementary diet is introduced, bacterial genera including
tryptophan catabolizing species such as Lactobacillus, Rumino-
coccus, Bacteroides, Peptostreptococcus and Clostridium become
abundant in the gut of infants99. Combined with the fact that
tryptophan catabolites via AHR activation modulate and educate
the immune system as reviewed above, this makes microbial
tryptophan catabolites in early life a very relevant area of
research, which has not received much attention. In mice, AHR
activation is required for the postnatal expansion of intestinal
lymphoid cells expressing the transcription factor RORγt and for
the formation of intestinal lymphoid follicles, which are immune
system components involved in maintenance of intestinal
homeostasis and resistance to infections103. Down these lines, it
was recently shown that maternally transmitted microbially
derived AHR ligands shape the early immune system of mouse
offspring by increasing intestinal group 3 innate lymphoid cells
and F4/80(+)CD11c(+) mononuclear cells104. Moreover, deliv-
ery mode and gestational age of infants are reported to affect
urinary levels of metabolites belonging to the tryptophan path-
way105. A recent study revealed that dietary protein depletion
compromised adaptive immune responses and altered tryptophan
amino acid homeostasis in human infant microbiota-transplanted
pigs infected with human rotavirus106, and another study in
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neonatal pigs showed that formula feeding compared to sow
feeding reduced enterochomafﬁn cell number and shifted tryp-
tophan metabolism from serotonin to tryptamine107. Collectively,
these studies suggest that factors such as maternal microbiota and
diet, delivery mode, gestational age, infant microbiota and diet
inﬂuence tryptophan metabolism in early life, which may be
essential for the development of intestinal barrier functions and
immune system.
Inﬂammatory bowel disease
During the last decade, IBD has been one of the most studied
human conditions linked to the gut microbiota. Interestingly,
serum levels of tryptophan are signiﬁcantly lower in IBD patients
than in healthy controls, and is particularly reduced in patients
with Crohn’s disease (CD) as compared to patients suffering from
ulcerative colitis (UC)108. In addition, plasma tryptophan levels
are reported to be reduced in CD109,110, whereas fecal tryptophan
levels are elevated compared to healthy individuals111. These
observations suggest that changes in tryptophan metabolism are
involved in the etiology of IBD. In line with this, a tryptophan
free diet increased susceptibility to DSS-induced inﬂammation in
mice112. Importantly, not only tryptophan appears to play a role
in the etiology of IBD. Also depletion of intestinal tryptophan
catabolites may affect the severity of IBD, as it was recently shown
that IBD patients have reduced fecal concentrations of the AHR
agonist IAA29. Consistent with this, AHR is downregulated in the
intestinal tissue of patients with IBD113 and AHR activation
protects humanized mice against colitis by induction of reg-
ulatory T cells114. Furthermore, IPA is selectively diminished in
circulating serum from human subjects with active colitis com-
pared to healthy individuals31, and oral administration of indole,
as well as IPA is found to ameliorate colonic inﬂammation in
mice31,115. Gut microbial tryptophan metabolism thus holds
promise as a therapeutic target in patients with IBD, provided
that future research will untangle the relations between the
individual tryptophan catabolites and the propensity of
inﬂammation.
Neurological diseases
Multiple sclerosis (MS) is a neurodegenerative autoimmune dis-
order. Astrocytes, a population of cells in the central nervous
system (CNS), are thought to play an important role in the
pathogenesis of MS. A recent study revealed that microbial cat-
abolites of dietary tryptophan combined with type I interferon
signaling activates AHR signaling in astrocytes and suppress CNS
inﬂammation in an experimental autoimmune encephalomyelitis
(EAE) animal model of MS116. In addition, they found decreased
circulating levels of AHR agonists in individuals with MS, sug-
gesting that imbalances in the uptake, production, or degradation
of AHR agonists may contribute to the pathogenesis of MS and
other autoimmune disorders116. In line herewith, Laquinimod, an
oral drug that is currently being evaluated for the treatment of MS
and Huntington’s disease (HD), a rare neurodegenerative disease,
was recently shown to have anti-inﬂammatory effects in EAE
mediated by AHR117. Interestingly, plasma levels of IPA were
signiﬁcantly lower in subjects with HD compared to healthy
controls30. Thus, targeting the gut microbial tryptophan meta-
bolism by modulating the endogenous gut microbiota or chan-
ging the diet may represent alternative strategies to prevent and
treat MS and other neurological diseases.
Future directions
Although several bacteria capable of producing tryptophan cat-
abolites have been identiﬁed (Table 1), the main contributors in
the human gut remain to a large extent unknown despite the large
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Fig. 3 Proposed strategy to identify tryptophan-catabolite-producing microbes and to investigate their role in human health and disease. Although a
number of tryptophan-catabolite producing microbes have currently been identiﬁed (Table 1), no studies have until now taken their starting point from
human data, meaning that we do not know the main bacterial producers of tryptophan catabolites in the human gut. Therefore, we suggest to start from
human studies and combine metagenomics and metabolomics data in order to pinpoint the most relevant and potential tryptophan-catabolite producing
microbes. Based on these associations, selected target species should be cultured in the laboratory and their in vitro production of tryptophan catabolites
should be assessed by growth experiments and metabolic proﬁling. Combined with knowledge about their genomes, this will allow the identiﬁcation of
genes responsible for generation of tryptophan catabolites. Knocking out identiﬁed genes of interest will subsequently allow for conﬁrmation of the
function of the gene and for testing the importance of the particular gene in relevant animal models as recently exempliﬁed21. Colonizing mice with a given
mutant strain and the wild-type counterpart will furthermore allow the investigation of modes of action of the tryptophan catabolites on e.g., intestinal
immune cells, intestinal barrier function, intestinal hormone secretion, the inherent gut microbiota, as well as on the immune cells in systemic circulation.
Together, this will provide new insights about the role of tryptophan catabolites, and lead to a better understanding of the gut microbiota in human health
and disease
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amount of fecal metagenomics data available. As we forge ahead
to determine the contributors, we propose to combine proﬁling of
microbes (metagenomics) with quantiﬁcation of tryptophan cat-
abolites (metabolomics) in stool samples from human cohorts.
This will allow us to identify important associations between
tryptophan catabolites and microbial species, which can be ver-
iﬁed using classic in vitro cultivation and metabolic phenotyping.
Since tryptophan catabolites are also produced by other micro-
organisms than bacteria, it is imperative that we move away from
proﬁling only the bacterial community and start exploring the
human gut microbiota across kingdoms. Once we identify the
relevant microorganisms and tryptophan catabolites in the gut of
infants, adults and elderly, we must identify the exact role of each
tryptophan catabolite in host (patho)physiology and unravel their
precise mechanisms in the different segments and cells of the
intestine, as well as in the different tissues by use of animal
models and by conducting human interventions (Fig. 3). In
addition, there is a need to identify the receptors recognizing the
metabolites. Furthermore, the AHR species-dependent ligand
preferences for tryptophan catabolites seen when comparing
different mammals22,47 underline the importance of studying
tryptophan catabolite interactions in human cells and not solely
in murine models. Currently, the connections between trypto-
phan catabolites and human health remain rather tentative, with
most data being associative or originating from mouse models.
Therefore, a more comprehensive understanding of the dynamics
of tryptophan catabolites and their functional implications in the
different stages of life from birth to old age, from health to disease
is needed. This may crucially extend our understanding of
intestinal host-microbial cross-talk in health and disease.
Received: 23 February 2018 Accepted: 3 July 2018
References
1. Tremaroli, V. & Bäckhed, F. Functional interactions between the gut
microbiota and host metabolism. Nature 489, 242–249 (2012).
2. Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Bäckhed, F. From Dietary
Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial
Metabolites. Cell 165, 1332–1345 (2016).
3. Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal Crosstalk
between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell.
Metab. 24, 41–50 (2016).
4. Koeth, R. A. et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in
red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013).
5. Wang, Z. et al. Gut ﬂora metabolism of phosphatidylcholine promotes
cardiovascular disease. Nature 472, 57–63 (2011).
6. Nyangale, E. P., Mottram, D. S. & Gibson, G. R. Gut microbial activity,
implications for health and disease: the potential role of metabolite analysis. J.
Proteome Res. 11, 5573–5585 (2012).
7. Evenepoel, P. et al. Amount and fate of egg protein escaping assimilation in
the small intestine of humans. Am. J. Physiol. 277, G935–G943 (1999).
8. Gibson, J. A., Sladen, G. E. & Dawson, A. M. Protein absorption and ammonia
production: the effects of dietary protein and removal of the colon. Br. J. Nutr.
35, 61–65 (1976).
9. Macfarlane, G. T., Cummings, J. H., Macfarlane, S. & Gibson, G. R. Inﬂuence
of retention time on degradation of pancreatic enzymes by human colonic
bacteria grown in a 3-stage continuous culture system. J. Appl. Bacteriol. 67,
520–527 (1989).
10. Roager, H. M. et al. Colonic transit time is related to bacterial metabolism and
mucosal turnover in the gut. Nat. Microbiol. 1, 16093 (2016). This study
demonstrates how a long colonic transit time in humans cause a shift in
bacterial catabolism from saccharolytic to proteolytic fermentation.
11. Geypens, B. et al. Inﬂuence of dietary protein supplements on the formation of
bacterial metabolites in the colon. Gut 41, 70–76 (1997).
12. Smith, E. A. & Macfarlane, G. T. Enumeration of human colonic bacteria
producing phenolic and indolic compounds: effects of pH, carbohydrate
availability and retention time on dissimilatory aromatic amino acid
metabolism. J. Appl. Bacteriol. 81, 288–302 (1996).
13. Vieira-Silva, S. et al. Species–function relationships shape ecological properties
of the human gut microbiome. Nat. Microbiol. 1, 16088 (2016).
14. Zelante, T. et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon
receptor and balance mucosal reactivity via interleukin-22. Immunity 39, 372–385
(2013). This study shows for the ﬁrst time how tryptophan catabolites protect
against fungus infections and intestinal inﬂammation.
15. Smith, T. A modiﬁcation of the method for determining the production of
indol by bacteria. J. Exp. Med. 2, 543–547 (1897).
16. Lee, J. H. & Lee, J. Indole as an intercellular signal in microbial communities.
FEMS Microbiol. Rev. 34, 426–444 (2010).
17. Elsden, S. R., Hilton, M. G. & Waller, J. M. The end products of the
metabolism of aromatic amino acids by clostridia. Arch. Microbiol. 107,
283–288 (1976).
18. Devlin, A. S. et al. Modulation of a Circulating Uremic Solute via Rational
Genetic Manipulation of the Gut Microbiota. Cell. Host. Microbe 20, 709–715
(2016).
19. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut
microﬂora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106,
3698–3703 (2009).
20. Williams, B. B. et al. Discovery and characterization of gut microbiota
decarboxylases that can produce the neurotransmitter tryptamine. Cell. Host.
Microbe 16, 495–503 (2014).
21. Dodd, D. et al. A gut bacterial pathway metabolizes aromatic amino acids into
nine circulating metabolites. Nature 551, 648–652 (2017). An elegant study
combining genetics and metabolic proﬁling to characterise a pathway of
Clostridium sporogenes that generates aromatic amino acid metabolites.
22. Wlodarska, M. et al. Indoleacrylic Acid Produced by Commensal
Peptostreptococcus Species Suppresses Inﬂammation. Cell. Host. Microbe 22,
25–37.e6 (2017).
23. Cervantes-Barragan, L. et al. Lactobacillus reuteri induces gut intraepithelial
CD4(+)CD8αα(+) T cells. Science 357, 806–810 (2017). This study reveals
that Lactobacillus reuteri via production of indole derivatives, activates
AHR which leads to reprogramming of intraepithelial CD4+ T cells into
immunoregulatory T cells.
24. Wilck, N. et al. Salt-responsive gut commensal modulates TH17 axis and
disease. Nature 551, 585–589 (2017).
25. Russell, W. R. et al. Major phenylpropanoid-derived metabolites in the human
gut can arise from microbial fermentation of protein. Mol. Nutr. Food Res. 57,
523–535 (2013). Systematic screening of the ability of colonic bacterial
species ferment aromatic amino acids including tryptophan catabolites.
26. Aragozzini, F., Ferrari, A., Pacini, N. & Gualandris, R. Indole-3-lactic acid as a
tryptophan metabolite produced by Biﬁdobacterium spp. Appl. Environ.
Microbiol. 38, 544–546 (1979).
27. Whitehead, T. R., Price, N. P., Drake, H. L. & Cotta, M. A. Catabolic Pathway
for the Production of Skatole and Indoleacetic Acid by the Acetogen
Clostridium drakei, Clostridium scatologenes, and Swine Manure. Appl.
Environ. Microbiol. 74, 1950–1953 (2008).
28. Darkoh, C., Chappell, C., Gonzales, C. & Okhuysen, P. A rapid and speciﬁc
method for the detection of indole in complex biological samples. Appl.
Environ. Microbiol. 81, 8093–8097 (2015).
29. Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism
of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 22, 598–605
(2016). The study provides evidence that defects in expression of factors
involved in innate immunity, such as CARD9, can alter the microbial
tryptophan catabolite production, which can then modify the host immune
response.
30. Rosas, H. D. et al. A systems-level ‘misunderstanding’: the plasma metabolome
in Huntington’s disease. Ann. Clin. Transl. Neurol. 2, 756–768 (2015).
31. Alexeev, E. E. et al. Microbiota-derived indole metabolites promote human
and murine intestinal homeostasis through regulation of interleukin-10
receptor. Am. J. Pathol. 188, 1183–1194 (2018).
32. Pavlova, T. et al. Urinary intermediates of tryptophan as indicators of the gut
microbial metabolism. Anal. Chim. Acta 987, 72–80 (2017).
33. Magni, G., Amici, A., Emanuelli, M., Raffaelli, N. & Ruggieri, S. Enzymology
of NAD+ synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 73, 135–182 (1999).
34. Hansen, E. B. Redox reactions in food fermentations. Curr. Opin. Food Sci. 19,
98–103 (2018).
35. Van der Meulen, R., Camu, N., Van Vooren, T., Heymans, C. & De Vuyst, L.
In vitro kinetic analysis of carbohydrate and aromatic amino acid metabolism
of different members of the human colon. Int. J. Food Microbiol. 124, 27–33
(2008).
36. Chen, H. & Fink, G. R. Feedback control of morphogenesis in fungi by
aromatic alcohols. Genes Dev. 20, 1150–1161 (2006).
37. Elleuch, L. et al. Bioactive Secondary Metabolites from a New Terrestrial
Streptomyces sp. TN262. Appl. Biochem. Biotechnol. 162, 579–593 (2010).
38. Landete, J. M., Rodríguez, H., De las Rivas, B. & Muñoz, R. High-added-value
antioxidants obtained from the degradation of wine phenolics by Lactobacillus
plantarum. J. Food Prot. 70, 2670–2675 (2007).
REVIEW ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05470-4
8 NATURE COMMUNICATIONS |  (2018) 9:3294 | DOI: 10.1038/s41467-018-05470-4 | www.nature.com/naturecommunications
39. Jin, M., Xu, C. & Zhang, X. The effect of tryptophol on the bacteriophage
infection in high-temperature environment. Appl. Microbiol. Biotechnol. 99,
8101–8111 (2015).
40. Zhu, F. & Jin, M. The effects of a thermophile metabolite, tryptophol, upon
protecting shrimp against white spot syndrome virus. Fish. Shellﬁsh. Immunol.
47, 777–781 (2015).
41. Orhan, I., Şener, B., Kaiser, M., Brun, R. & Tasdemir, D. Inhibitory Activity of
Marine Sponge-Derived Natural Products against Parasitic Protozoa. Mar.
Drugs 8, 47–58 (2010).
42. Honoré, A. H. et al. Metabolic footprinting for investigation of antifungal
properties of Lactobacillus paracasei. Anal. Bioanal. Chem. 408, 83–96
(2016).
43. Narayanan, T. K. & Rao, G. R. Beta-indoleethanol and beta-indolelactic acid
production by Candida species: their antibacterial and autoantibiotic action.
Antimicrob. Agents Chemother. 9, 375–380 (1976).
44. Lee, J.-H. et al. Indole-associated predator-prey interactions between the
nematode Caenorhabditis elegans and bacteria. Environ. Microbiol. 19,
1776–1790 (2017).
45. Bommarius, B. et al. A Family of Indoles Regulate Virulence and Shiga Toxin
Production in Pathogenic E. coli. PLoS ONE 8, e54456 (2013).
46. Cheng, Y. et al. Aryl Hydrocarbon Receptor Activity of Tryptophan
Metabolites in Young Adult Mouse Colonocytes. Drug Metab. Dispos. 43,
1526–1543 (2015).
47. Hubbard, T. D. et al. Adaptation of the human aryl hydrocarbon receptor to
sense microbiota-derived indoles. Sci. Rep. 5, 12689 (2015). This paper shows
adaptation of human AHR to bind indole as a selective human AHR agonist,
suggesting a degree of evolutionary adaption by the AHR.
48. Stockinger, B., Di Meglio, P., Gialitakis, M. & Duarte, J. H. The aryl
hydrocarbon receptor: multitasking in the immune system. Annu. Rev.
Immunol. 32, 403–432 (2014).
49. Quintana, F. J. et al. Control of T(reg) and T(H)17 cell differentiation by the
aryl hydrocarbon receptor. Nature 453, 65–71 (2008).
50. Bessede, A. et al. Aryl hydrocarbon receptor control of a disease tolerance
defence pathway. Nature 511, 184–190 (2014).
51. Gandhi, R. et al. Activation of the aryl hydrocarbon receptor induces human
type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat. Immunol.
11, 846–853 (2010).
52. Poland, A., Palen, D. & Glover, E. Analysis of the four alleles of the murine
aryl hydrocarbon receptor. Mol. Pharmacol. 46, 915–921 (1994).
53. Ramadoss, P. & Perdew, G. H. Use of 2-Azido-3-[125I]iodo-7,8-
dibromodibenzo-p-dioxin as a Probe to Determine the Relative Ligand
Afﬁnity of Human versus Mouse Aryl Hydrocarbon Receptor in Cultured
Cells. Mol. Pharmacol. 66, 129–136 (2004).
54. Jin, U.-H. et al. Microbiome-Derived Tryptophan Metabolites and Their Aryl
Hydrocarbon Receptor-Dependent Agonist and Antagonist Activities. Mol.
Pharmacol. 85, 777–788 (2014).
55. Takamura, T. et al. Lactobacillus bulgaricus OLL1181 activates the aryl
hydrocarbon receptor pathway and inhibits colitis. Immunol. Cell Biol. 89,
817–822 (2011).
56. Noack, M. & Miossec, P. Th17 and regulatory T cell balance in autoimmune
and inﬂammatory diseases. Autoimmun. Rev. 13, 668–677 (2014).
57. Sonowal, R. et al. Indoles from commensal bacteria extend healthspan. Proc.
Natl Acad. Sci. USA 114, E7506–E7515 (2017).
58. Bansal, T., Alaniz, R. C., Wood, T. K. & Jayaraman, A. The bacterial signal
indole increases epithelial-cell tight-junction resistance and attenuates
indicators of inﬂammation. Proc. Natl Acad. Sci. USA 107, 228–233
(2010). The ﬁrst study to propose that indole strengthens epithelial cell-
barrier properties and attenuate inﬂammation.
59. Shimada, Y. et al. Commensal bacteria-dependent indole production enhances
epithelial barrier function in the colon. PLoS ONE 8, e80604 (2013).
60. Venkatesh, M. et al. Symbiotic Bacterial Metabolites Regulate Gastrointestinal
Barrier Function via the Xenobiotic Sensor PXR and Toll-like Receptor 4.
Immunity 41, 296–310 (2014).
61. Garg, A. et al. Pregnane X Receptor Activation Attenuates Inﬂammation-
Associated Intestinal Epithelial Barrier Dysfunction by Inhibiting Cytokine-
Induced Myosin Light-Chain Kinase Expression and c-Jun N-Terminal Kinase
1/2 Activation. J. Pharmacol. Exp. Ther. 359, 91–101 (2016).
62. Jennis, M. et al. Microbiota-derived tryptophan indoles increase after gastric
bypass surgery and reduce intestinal permeability in vitro and in vivo.
Neurogastroenterol. Motil. 30, e13178 (2017).
63. Chimerel, C. et al. Bacterial metabolite indole modulates incretin secretion
from intestinal enteroendocrine L cells. Cell Rep. 9, 1202–1208 (2014). This
paper demonstrates that GLP-1 secretion from enteroendocrine L cells is
modulated by exposure to indole at concentrations similar to those found in
the human large intestine.
64. Holst, J. J. The Physiology of Glucagon-like Peptide 1. Physiol. Rev. 87,
1409–1439 (2007).
65. de Mello, V. D. et al. Indolepropionic acid and novel lipid metabolites are
associated with a lower risk of type 2 diabetes in the Finnish Diabetes
Prevention Study. Sci. Rep. 7, 46337 (2017).
66. Abildgaard, A., Elfving, B., Hokland, M., Wegener, G. & Lund, S. The
microbial metabolite indole-3-propionic acid improves glucose metabolism in
rats, but does not affect behaviour. Arch. Physiol. Biochem. 1–7, https://doi.
org/10.1080/13813455.2017.1398262 (2017).
67. Reimann, F., Tolhurst, G. & Gribble, F. M. G-Protein-Coupled Receptors in
Intestinal Chemosensation. Cell. Metab. 15, 421–431 (2012).
68. Husted, A. S., Trauelsen, M., Rudenko, O., Hjorth, S. A. & Schwartz, T. W.
GPCR-Mediated Signaling of Metabolites. Cell. Metab. 25, 777–796
(2017).
69. Takaki, M., Mawe, G. M., Barasch, J. M., Gershon, M. D. & Gershon, M. D.
Physiological responses of guinea-pig myenteric neurons secondary to the
release of endogenous serotonin by tryptamine. Neuroscience 16, 223–240
(1985).
70. Mawe, G. M. & Hoffman, J. M. Serotonin signalling in the gut—functions,
dysfunctions and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 10,
473–486 (2013).
71. Vandeputte, D. et al. Stool consistency is strongly associated with gut
microbiota richness and composition, enterotypes and bacterial growth rates.
Gut 65, 57–62 (2015).
72. Lacy, B. E., Chey, W. D. & Lembo, A. J. New and Emerging Treatment
Options for Irritable Bowel Syndrome. Gastroenterol. Hepatol. (N. Y) 11, 1–19
(2015).
73. Png, C. W. et al. Mucolytic bacteria with increased prevalence in IBD mucosa
augment in vitro utilization of mucin by other bacteria. Am. J. Gastroenterol.
105, 2420–2428 (2010).
74. Joossens, M. et al. Dysbiosis of the faecal microbiota in patients with Crohn’s
disease and their unaffected relatives. Gut 60, 631–637 (2011).
75. Tailford, L. E. et al. Discovery of intramolecular trans-sialidases in human gut
microbiota suggests novel mechanisms of mucosal adaptation. Nat. Commun.
6, 7624 (2015).
76. Hoffmann, T. W. et al. Microorganisms linked to inﬂammatory bowel disease-
associated dysbiosis differentially impact host physiology in gnotobiotic mice.
Isme. J. 10, 460–477 (2016).
77. Qin, J. et al. A human gut microbial gene catalogue established by
metagenomic sequencing. Nature 464, 59–65 (2010).
78. Sagheddu, V., Patrone, V., Miragoli, F., Puglisi, E. & Morelli, L. Infant Early
Gut Colonization by Lachnospiraceae: High Frequency of Ruminococcus
gnavus. Front. Pediatr. 4, 57 (2016).
79. Schirmer, M. et al. Linking the Human Gut Microbiome to Inﬂammatory
Cytokine Production Capacity. Cell 167, 1125–1136.e8 (2016).
80. Chyan, Y. J. et al. Potent neuroprotective properties against the Alzheimer
beta-amyloid by an endogenous melatonin-related indole structure, indole-3-
propionic acid. J. Biol. Chem. 274, 21937–21942 (1999).
81. Hwang, I. K. et al. Indole-3-propionic acid attenuates neuronal damage and
oxidative stress in the ischemic hippocampus. J. Neurosci. Res. 87, 2126–2137
(2009).
82. Karbownik, M., Stasiak, M., Zasada, K., Zygmunt, A. & Lewinski, A.
Comparison of potential protective effects of melatonin, indole-3-propionic
acid, and propylthiouracil against lipid peroxidation caused by potassium
bromate in the thyroid gland. J. Cell. Biochem. 95, 131–138 (2005).
83. Karbownik, M., Stasiak, M., Zygmunt, A., Zasada, K. & Lewiński, A. Protective
effects of melatonin and indole-3-propionic acid against lipid peroxidation,
caused by potassium bromate in the rat kidney. Cell. Biochem. Funct. 24,
483–489 (2006).
84. Joshi, G. & Johnson, J. A. The Nrf2-ARE pathway: a valuable therapeutic
target for the treatment of neurodegenerative diseases. Recent Pat. CNS Drug
Discov. 7, 218–229 (2012).
85. Lu, M.-C. et al. An inhibitor of the Keap1-Nrf2 protein-protein interaction
protects NCM460 colonic cells and alleviates experimental colitis. Sci. Rep. 6,
26585 (2016).
86. Krishnan, S. et al. Gut Microbiota-Derived Tryptophan Metabolites Modulate
Inﬂammatory Response in Hepatocytes and Macrophages. Cell Rep. 23,
1099–1111 (2018).
87. Kado, S. et al. Aryl hydrocarbon receptor signaling modiﬁes Toll-like receptor-
regulated responses in human dendritic cells. Arch. Toxicol. 91, 2209–2221
(2016).
88. Jin, U.-H. et al. Short Chain Fatty Acids Enhance Aryl Hydrocarbon (Ah)
Responsiveness in Mouse Colonocytes and Caco-2 Human Colon Cancer
Cells. Sci. Rep. 7, 10163 (2017).
89. Banoglu, E., Jha, G. G. & King, R. S. Hepatic microsomal metabolism of indole
to indoxyl, a precursor of indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet.
26, 235–240 (2001).
90. Wu, I.-W. et al. p-Cresyl sulphate and indoxyl sulphate predict progression of
chronic kidney disease. Nephrol. Dial. Transplant. 26, 938–947 (2011).
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05470-4 REVIEW ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3294 | DOI: 10.1038/s41467-018-05470-4 | www.nature.com/naturecommunications 9
91. Kim, H. Y. et al. Indoxyl sulfate (IS)-mediated immune dysfunction provokes
endothelial damage in patients with end-stage renal disease (ESRD). Sci. Rep.
7, 3057 (2017).
92. Schroeder, J. C. et al. The Uremic Toxin 3-Indoxyl Sulfate Is a Potent
Endogenous Agonist for the Human Aryl Hydrocarbon Receptor.
Biochemistry 49, 393–400 (2010).
93. Motojima, M., Hosokawa, A., Yamato, H., Muraki, T. & Yoshioka, T. Uremic
toxins of organic anions up-regulate PAI-1 expression by induction of NF-κB
and free radical in proximal tubular cells. Kidney Int. 63, 1671–1680 (2003).
94. Niwa, T. & Ise, M. Indoxyl sulfate, a circulating uremic toxin, stimulates the
progression of glomerular sclerosis. J. Lab. Clin. Med. 124, 96–104 (1994).
95. Dou, L. et al. The uremic solutes p-cresol and indoxyl sulfate inhibit
endothelial proliferation and wound repair. Kidney Int. 65, 442–451 (2004).
96. Dou, L. et al. The uremic solute indoxyl sulfate induces oxidative stress in
endothelial cells. J. Thromb. Haemost. 5, 1302–1308 (2007).
97. Yatsunenko, T. et al. Human gut microbiome viewed across age and
geography. Nature 486, 222–227 (2012).
98. Bergström, A. et al. Establishment of intestinal microbiota during early life: A
longitudinal, explorative study of a large cohort of Danish infants. Appl.
Environ. Microbiol. 80, 2889–2900 (2014).
99. Laursen, M. F. et al. Infant Gut Microbiota Development Is Driven by
Transition to Family Foods Independent of Maternal Obesity. mSphere 1,
e00069–15 (2016).
100. Laursen, M. F., Bahl, M. I., Michaelsen, K. F. & Licht, T. R. First Foods and
Gut Microbes. Front. Microbiol. 8, 356 (2017).
101. Bäckhed, F. et al. Dynamics and stabilization of the human gut microbiome
during the ﬁrst year of life. Cell. Host. Microbe 17, 690–703 (2015).
102. Bazanella, M. et al. Randomized controlled trial on the impact of early-life
intervention with biﬁdobacteria on the healthy infant fecal microbiota and
metabolome. Am. J. Clin. Nutr. 106, 1274–1286 (2017).
103. Kiss, E. A. et al. Natural Aryl Hydrocarbon Receptor Ligands Control
Organogenesis of Intestinal Lymphoid Follicles. Sci. (80-.). 334, 1561–1565
(2011).
104. Gomez de Aguero, M. et al. The maternal microbiota drives early postnatal
innate immune development. Sci. (80-.). 351, 1296–1302 (2016). First study to
suggest that tryptophan catabolites may shape the composition and function
of early postnatal immunity.
105. Hill, C. J. et al. Evolution of gut microbiota composition from birth to
24 weeks in the INFANTMET Cohort. Microbiome 5, 21 (2017).
106. Fischer, D. D. et al. Protein Malnutrition Alters Tryptophan and Angiotensin-
Converting Enzyme 2 Homeostasis and Adaptive Immune Responses in
Human Rotavirus-Infected Gnotobiotic Pigs with Human Infant Fecal
Microbiota Transplant. Clin. Vaccin. Immunol. 24, e00172–17 (2017).
107. Saraf, M. K. et al. Formula diet driven microbiota shifts tryptophan
metabolism from serotonin to tryptamine in neonatal porcine colon.
Microbiome 5, 77 (2017).
108. Nikolaus, S. et al. Increased Tryptophan Metabolism is Associated With
Activity of Inﬂammatory Bowel Diseases. Gastroenterology 153, 1504–1516.e2
(2017).
109. Hisamatsu, T. et al. Novel, Objective, Multivariate Biomarkers Composed of
Plasma Amino Acid Proﬁles for the Diagnosis and Assessment of
Inﬂammatory Bowel Disease. PLoS ONE 7, e31131 (2012).
110. Gupta, N. K. et al. Serum analysis of tryptophan catabolism pathway:
correlation with Crohn’s disease activity. Inﬂamm. Bowel Dis. 18, 1214–1220
(2012).
111. Jansson, J. et al. Metabolomics reveals metabolic biomarkers of Crohn’s
disease. PLoS ONE 4, e6386 (2009).
112. Hashimoto, T. et al. ACE2 links amino acid malnutrition to microbial ecology
and intestinal inﬂammation. Nature 487, 477–481 (2012).
113. Monteleone, I. et al. Aryl hydrocarbon receptor-induced signals up-regulate
IL-22 production and inhibit inﬂammation in the gastrointestinal tract.
Gastroenterology 141, 237–248 (2011). 248.e1.
114. Goettel, J. A. et al. AHR Activation Is Protective against Colitis Driven by T
Cells in Humanized Mice. Cell Rep. 17, 1318–1329 (2016).
115. Whitﬁeld-Cargile, C. M. et al. The microbiota-derived metabolite indole
decreases mucosal inﬂammation and injury in a murine model of NSAID
enteropathy. Gut Microbes 7, 246–261 (2016).
116. Rothhammer, V. et al. Type I interferons and microbial metabolites of
tryptophan modulate astrocyte activity and central nervous system
inﬂammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586–597
(2016). The study provides evidence that tryptophan metabolites modulate
the activity of central nervous system resident cells and suppress
neuroinﬂammation.
117. Kaye, J. et al. Laquinimod arrests experimental autoimmune encephalomyelitis
by activating the aryl hydrocarbon receptor. Proc. Natl Acad. Sci. 113,
E6145–E6152 (2016).
118. Honeyﬁeld, D. C. & Carlson, J. R. Effect of Indoleacetic Acid and Related
Indoles on Lactobacillus sp. Strain 11201 Growth, Indoleacetic Acid
Catabolism, and 3-Methylindole Formation. Appl. Environ. Microbiol. 56,
1373–1377 (1990).
Acknowledgements
The authors thank Martin Frederik Laursen and Egon Bech Hansen for helpful discus-
sions. This work was supported by the Innovation Fund Denmark (grant no. 11-116163/
0603-00487B; Center for Gut, Grain and Greens).
Author contributions
H.M.R. drafted the text and ﬁgures with inputs from T.R.L. Both authors revised and
ﬁnalized the manuscript for publication.
Additional information
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
REVIEW ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05470-4
10 NATURE COMMUNICATIONS |  (2018) 9:3294 | DOI: 10.1038/s41467-018-05470-4 | www.nature.com/naturecommunications
